This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent. Top assignee: Cantero Therapeutics, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Elham Akbariromani: Innovator in Glycolate Oxidase Inhibition
Introduction
Elham Akbariromani is a notable inventor based in Laval, Canada. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit glycolate oxidase. Her work is crucial for addressing medical conditions such as primary hyperoxaluria and kidney stones.
Latest Patents
Elham holds a patent for "Triazole glycolate oxidase inhibitors." This invention provides triazole carboxylic acids and related compounds, along with their pharmaceutically acceptable salts, which are effective as glycolate oxidase inhibitors. The patent also describes pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH), and kidney stones.
Career Highlights
Elham is currently employed at Cantero Therapeutics, Inc., where she continues to advance her research and development efforts. Her innovative approach and dedication to her work have positioned her as a key figure in her field.
Collaborations
Elham collaborates with esteemed colleagues, including Hans Maag and Miguel Xavier Fernandes, who contribute to her research endeavors and enhance the impact of her work.
Conclusion
Elham Akbariromani's contributions to the field of pharmaceutical sciences through her innovative inventions are noteworthy. Her work in developing glycolate oxidase inhibitors showcases her commitment to improving medical treatments and patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile